Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 822 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original Cita con resumen
Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 2015;8:189-99. [Ref.ID 99700]
23.Enlace a cita original Cita con resumen
Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol 2015;80:179-81. [Ref.ID 99474]
24.Tiene citas relacionadas Cita con resumen
Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann Intern Med 2015;163:64-5. [Ref.ID 99337]
25.Tiene citas relacionadas Cita con resumen
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry US, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ. Effect of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [Ref.ID 99336]
26.Tiene citas relacionadas
Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom?. N Engl J Med 2015;372:1564-5. [Ref.ID 99059]
27.Tiene citas relacionadas Cita con resumen
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]
28. Cita con resumen
Anónimo. Lomitapide. Prescrire 2015;35:168-71. [Ref.ID 98923]
29. Cita con resumen
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]
30. Cita con resumen
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]
31. Cita con resumen
32.Enlace a cita original
Anónimo. Los lípidos como factor de riesgo cardiovascular: tratamiento farmacológico. Infac: Información Farmacoterapéutica de la Comarca 2014;22:37-43. [Ref.ID 98319]
33. Cita con resumen
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Slein EA, for the DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19. [Ref.ID 97589]
34. Cita con resumen
Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review. Ann Intern Med 2014;160:468-76. [Ref.ID 97523]
35. Cita con resumen
Albert L, González-Clemente JM. Prevención cardiovascular primaria con estatinas en la diabetes mellitus tipo 2: ¿es hora de cambiar de estrategia?. Med Clin (Barc) 2014;142:358-9. [Ref.ID 97378]
36.Enlace a cita original
Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]
37.Tiene citas relacionadas
Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med 2014;160:361-2. [Ref.ID 97294]
39.Tiene citas relacionadas Cita con resumen
Downs J, Good C. New cholesterol guidelines: has Godot finally arrived?. Ann Intern Med 2014;160:354-5. [Ref.ID 97292]
40.
Krumholz HM. Target cardiovascular risk rather than cholesterol concrentration. BMJ 2013;347:7. [Ref.ID 96710]
Seleccionar todas
 
<< anterior 21 a 40 de 822 siguiente >>